行业洞察：国产新药迈入临床，癌痛治疗开辟新路径

Investment Rating - The report does not explicitly state an investment rating for the industry [1]. Core Insights - Adult cancer pain management is a systematic project aimed at achieving comprehensive pain control through standardized assessment, individualized treatment, and multidisciplinary collaboration [4]. - Cancer pain is a prevalent symptom among cancer patients, with a high incidence rate of 44.5%, and nearly one-third of patients suffer from moderate to severe pain [11]. - The adult cancer pain treatment market in China is expected to grow from 3.76 billion CNY in 2020 to 6.36 billion CNY by 2029, with a compound annual growth rate (CAGR) of 6.8% from 2020 to 2024 and 5.3% from 2025 to 2029 [20]. Summary by Sections Cancer Pain Management - Cancer pain management involves a comprehensive approach that includes pain screening, assessment, and management tailored to the patient's overall treatment goals [3][4]. - The management process is based on standardized screening and dynamic assessment, following principles of regularity, quantification, comprehensiveness, and dynamism [4]. Epidemiological Characteristics - Cancer pain has a high prevalence among patients, particularly in advanced stages, where over 80% experience pain [11]. - The main causes of cancer pain are tumor progression (over 90%) and treatment-related pain (approximately 20%) [11]. - Pain types include nociceptive pain (around 60%), neuropathic pain (19%), and mixed pain (20%) [11]. Treatment Medications - Common medications for cancer pain include weak opioids (e.g., codeine, tramadol), strong opioids (e.g., morphine, fentanyl), non-steroidal anti-inflammatory drugs (NSAIDs), and acetaminophen [15][16]. - There is a shift towards the development of non-opioid medications to provide safer and sustainable pain management options [16]. Market Outlook - The adult cancer pain treatment market is projected to expand significantly due to increasing clinical needs and the introduction of innovative non-opioid drugs [19][20]. - The treatment rate for cancer pain is expected to rise from approximately 70% to 90% by 2029, indicating a growing population receiving standardized treatment [20]. Innovation Trends - Treatment strategies are transitioning from reliance on opioids to a multimodal approach that includes NSAIDs and adjuvant analgesics [26]. - The focus on non-opioid innovative drugs is becoming a breakthrough direction in drug development [26]. - There is an emphasis on personalized medication management and the establishment of a comprehensive management network through medical alliances [26][27].